1. Home
  2. OXM vs ADCT Comparison

OXM vs ADCT Comparison

Compare OXM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Industries Inc.

OXM

Oxford Industries Inc.

HOLD

Current Price

$37.42

Market Cap

579.9M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.10

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXM
ADCT
Founded
1942
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
579.9M
484.4M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
OXM
ADCT
Price
$37.42
$4.10
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$44.80
$7.50
AVG Volume (30 Days)
214.1K
812.5K
Earning Date
03-10-2026
01-01-0001
Dividend Yield
7.08%
N/A
EPS Growth
53.66
44.90
EPS
N/A
N/A
Revenue
$1,516,601,000.00
$70,837,000.00
Revenue This Year
N/A
$14.96
Revenue Next Year
$1.68
$1.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.84
52 Week Low
$30.57
$1.05
52 Week High
$64.55
$4.80

Technical Indicators

Market Signals
Indicator
OXM
ADCT
Relative Strength Index (RSI) 43.80 51.41
Support Level $35.48 $3.25
Resistance Level $42.12 $4.71
Average True Range (ATR) 1.78 0.25
MACD -0.29 -0.02
Stochastic Oscillator 12.08 29.76

Price Performance

Historical Comparison
OXM
ADCT

About OXM Oxford Industries Inc.

Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: